The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Translating Molecular Pathology Into Cancer Diagnostics
Funder
National Health and Medical Research Council
Funding Amount
$479,882.00
Summary
The aim of this research is focussed on translation of basic science through to the clinic by introducing novel cancer diagnostics and technologies. Other integral aims are to identify new changes in DNA and other cancer cell markers in patients, assess the clinical utility of these as biomarkers (surrogates of cancer behaviour) and to conduct novel clinical trials with newly identified molecular targets of cancer and new therapeutics and combinations to assess their efficacy.
Molecular Determinants Of Progression And Treatment Response In Melanoma
Funder
National Health and Medical Research Council
Funding Amount
$467,068.00
Summary
Melanoma, a skin malignancy of pigment cells, is a major Australian health problem and is the commonest cancer in young adults. This project utilises the resources of the world’s largest melanoma treatment service and aims to develop a scientific basis for 1) improved management of individuals at high risk for melanoma progression, and 2) improved treatment of patients with early and disseminated melanoma, in an era of rapid change in the prospects of successfully treating this dangerous cancer.
Melanoma incidence continues to rise & it remains a leading cause of cancer death in young adults. Prevention & early detection are foundations of disease control. Drug treatments for advanced disease have recently begun to extend survival but remain ineffective in many. Utilising the extensive resources of Melanoma Institute Australia (world's largest melanoma treatment centre), this research seeks to improve outcomes of patients with difficult to treat & aggressive melanomas.
Neurobiology Of Childhood Speech And Language Disorders: Advancing Diagnosis, Prognosis And Management
Funder
National Health and Medical Research Council
Funding Amount
$467,961.00
Summary
Half a million Australian children have a speech/language disorder, tripling their changes of poor academic outcomes, limited employment options and social isolation. Current speech therapy is outdated, focusing on symptoms and ignoring important evidence on underlying aetiologies. I will transform detection, diagnosis and treatment of speech/language disorders to optimise patient outcomes, by identifying and translating findings on genes and brain pathways leading to these conditions.
Major advances in cancer treatment has been made by identifying gene mutations in cancers to which the cancer is “addicted”, such that turning off the effects of the mutations leads to death of the cancer cells. Grant McArthur has been successful in applying this principle to rare types of sarcoma bringing his work to routine clinical practice globally. In this application he will investigate targeting the BRAF, KIT and MYC genes focusing on melanoma, a major cancer problem in Australia.
This program of work focuses on smoking related lung diseases including chronic bronchitis and emphysema, and lung cancer, as well as diseases affecting the blood vessels in the lungs. The work includes basic cell biology and human clinical trials.There is a high likelihood that new approaches to treating lung disease will emerge.
Molecular Imaging To Advance Treatment Of Dementia
Funder
National Health and Medical Research Council
Funding Amount
$412,419.00
Summary
Molecular imaging using a scan technique called positron emission tomography, enables detection and measurement of specific pathological features of disease such as the amyloid plaques of Alzheimer’s disease. This project will develop this technology for other aspects of brain disorders including dementias, Parkinson’s disease, traumatic brain injury and schizophrenia and use it to assist development of therapies and improve clinical diagnosis nation wide.
Translating Advances In Molecular Oncology Into Improved Care For Patients With Haematological Malignancies
Funder
National Health and Medical Research Council
Funding Amount
$411,327.00
Summary
The purpose of my research is to develop and integrate into routine practice better treatment paradigms for patients with blood cancers – leukaemias, lymphomas, myeloma. My research seeks to (i) bring a new class of anti-cancer targeted therapy, inhibitors of Bcl-2, into routine care; (ii) discover the genetic changes that explain why slow growing lymphoid cancers change into rapidly fatal lymphomas; and (iii) integrate new molecular tests into the management of patients with acute leukaemia.
The growing momentum towards elimination of malaria and the need to control of drug-resistant parasites means that new drugs and vaccines are needed. In this Fellowship I will use the human malaria challenge system that I have developed to test whether new drugs and vaccines for malaria are working sufficiently well to justify their full development. In this system healthy volunteers are deliberately infected with malaria and then cured before they become unwell.